glp-1; obesity; weight loss; lifestyle

In this episode of Science Quickly, Scientific American’s associate health editor Lauren Young joins host Kendra Pierre-Louis to talk about how the story of GLP‑1 drugs such as Ozempic, Wegovy and Mounjaro is evolving. We trace GLP-1s’ origins as type 2 diabetes treatments, their rise as...

Are GLP-1 agonists like Ozempic and Mounjaro the future of healthcare or a risk to your health? We break down the latest data on weight loss medication efficacy, common side effects, and the truth about muscle mass loss (sarcopenia). In This Episode: Dr. Jordan Feigenbaum and Dr. Austin...

In this episode, Dr. Spencer Nadolsky discusses the transformative role of GLP-1 medications in obesity treatment. He explains the mechanism of GLP-1, its rise in popularity, associated risks, and the importance of personalized medicine. The conversation also touches on the significance of...

In this episode of You Are Not Broken, Dr. Kelly Casperson sits down with endocrinologist and obesity medicine expert Dr. Rocio Salas-Whalen for a deep dive into GLP-1 medications (like Ozempic, Wegovy, and Mounjaro). They cover everything you should be asking but probably haven’t heard...

The guest speakers says it all LOL! The Obesity Society (TOS) convened a panel of leading experts in obesity medicine, pharmacy, and regulatory law on March 19, 2025, to discuss the growing concerns surrounding the use of compounded GLP-1s for weight management and diabetes treatment. The...

Ross Arena, PhD, Professor and Head of the Department of Physical Therapy, College of Applied Health Sciences, at the University of Illinois at Chicago, reviews his article appearing in the December 2024 issue of Mayo Clinic Proceedings, where he finds promise in the newly emerging medical...